{"id":991262,"date":"2026-08-06T10:31:09","date_gmt":"2026-08-06T14:31:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/"},"modified":"2026-08-06T10:31:09","modified_gmt":"2026-08-06T14:31:09","slug":"madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/","title":{"rendered":"Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference"},"content":{"rendered":"
\n

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th<\/sup> Annual Growth Conference on\u00a0Tuesday, Aug. 11, 2026\u00a0at\u00a012:00 P.M. EDT.<\/p>\n

The presentation will be webcast live and may be accessed\u00a0here<\/a>\u00a0or by visiting Madrigal\u2019s Investor Relations Events and Presentations\u00a0page<\/a>. A replay of the webcast will be available after the event.<\/p>\n

\n About Madrigal Pharmaceuticals<\/strong>
\n
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal\u2019s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-\u03b2 agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit\u00a0www.madrigalpharma.com<\/a>.<\/p>\n

\n Investor Contact<\/strong>
\n
Tina Ventura, IR@madrigalpharma.com<\/a><\/p>\n

\n Media Contact<\/strong>
\n
Christopher Frates, media@madrigalpharma.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on\u00a0Tuesday, Aug. 11, 2026\u00a0at\u00a012:00 P.M. EDT. The presentation will be webcast live and may be accessed\u00a0here\u00a0or by visiting Madrigal\u2019s Investor Relations Events and Presentations\u00a0page. A replay of the webcast will be available after the event. About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal\u2019s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-\u03b2 agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both … <\/p>\n

Continue reading “Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-991262","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMadrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on\u00a0Tuesday, Aug. 11, 2026\u00a0at\u00a012:00 P.M. EDT. The presentation will be webcast live and may be accessed\u00a0here\u00a0or by visiting Madrigal\u2019s Investor Relations Events and Presentations\u00a0page. A replay of the webcast will be available after the event. About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal\u2019s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-\u03b2 agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both … Continue reading "Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-06T14:31:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDQwMyM3NzYxMTI5IzIwMDYyMTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference\",\"datePublished\":\"2026-08-06T14:31:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\\\/\"},\"wordCount\":192,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDQwMyM3NzYxMTI5IzIwMDYyMTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\\\/\",\"name\":\"Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDQwMyM3NzYxMTI5IzIwMDYyMTM=\",\"datePublished\":\"2026-08-06T14:31:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDQwMyM3NzYxMTI5IzIwMDYyMTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDQwMyM3NzYxMTI5IzIwMDYyMTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/","og_locale":"en_US","og_type":"article","og_title":"Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - Market Newsdesk","og_description":"CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on\u00a0Tuesday, Aug. 11, 2026\u00a0at\u00a012:00 P.M. EDT. The presentation will be webcast live and may be accessed\u00a0here\u00a0or by visiting Madrigal\u2019s Investor Relations Events and Presentations\u00a0page. A replay of the webcast will be available after the event. About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal\u2019s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-\u03b2 agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both … Continue reading \"Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-06T14:31:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDQwMyM3NzYxMTI5IzIwMDYyMTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference","datePublished":"2026-08-06T14:31:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/"},"wordCount":192,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDQwMyM3NzYxMTI5IzIwMDYyMTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/","name":"Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDQwMyM3NzYxMTI5IzIwMDYyMTM=","datePublished":"2026-08-06T14:31:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDQwMyM3NzYxMTI5IzIwMDYyMTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDQwMyM3NzYxMTI5IzIwMDYyMTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/991262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=991262"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/991262\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=991262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=991262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=991262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}